Clinical Trial Update: A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of MDX-1100 in patients with active ulcerative colitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• MDX-1100

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Ulcerative Colitis | Phase 1 | Status: COMPLETED